Dr. Eck has over 15 years of leadership experience in the development of oncology drugs and related biomarkers. Prior to joining Aravive, he was Vice President of Oncology Medical Sciences at Astellas Pharma Global Development, Inc. Previous to that, he served as Vice President, Translational Medicine & Pharmacogenomics at Eli Lilly and Company, where his group developed the biomarkers and companion diagnostics needed for study-specific decision making and for tailoring biotherapeutics to unique patient populations. Prior to joining Lilly, he served in a variety of oncology and neuroscience drug development leadership roles at Pfizer, Inc. Dr. Eck is a board-certified Hematologist, who holds a Ph.D. in chemistry from Harvard University and received his M.D. degree from the University of Mississippi School of Medicine. He serves on the Board of Directors of Luminex Corporation, is a Fellow of the American Association for the Advancement of Science, and is Chairman of the Board of Directors of the Personalized Medicine Coalition. He is also a member of the University of Texas MD Anderson Cancer Center President’s Advisory Board for the Moonshot Program.